Survodutide: The Weight Loss Drug That Also Treats Fatty Liver Disease (South Africa 2026 Guide)

The GLP-1 weight loss drug revolution keeps accelerating. You have probably heard of Ozempic, Mounjaro, and maybe even retatrutide. But there is a new contender that does something none of them were specifically designed to do: treat fatty liver disease and obesity at the same time.

Meet survodutide (BI 456906), a dual GLP-1/glucagon agonist developed by Boehringer Ingelheim and Zealand Pharma. It is generating serious excitement because it could help millions of South Africans who are dealing with both excess weight and the silent epidemic of fatty liver disease -- now officially called MASH (metabolic dysfunction-associated steatohepatitis).

What Is Survodutide and How Does It Work?

Survodutide is a once-weekly injectable peptide that activates two hormone receptors at the same time:

• GLP-1 (glucagon-like peptide-1) -- the same pathway targeted by Ozempic (semaglutide) and Wegovy. It suppresses appetite, slows gastric emptying, and improves blood sugar control.
• Glucagon receptor -- this is the key differentiator. Glucagon increases energy expenditure (your body burns more calories at rest), promotes the breakdown of fat stored in the liver, and drives lipid oxidation. This is why survodutide is particularly effective against fatty liver disease.

Think of the glucagon component as a metabolic accelerator. While the GLP-1 side reduces how much you eat, the glucagon side ramps up how much energy your body burns -- and specifically targets the dangerous fat deposits in your liver.

Clinical Trial Results: Weight Loss

The Phase 2 obesity trial results for survodutide were published in the New England Journal of Medicine (Blueher M et al., 2024). Here is the dose-response data over 46 weeks:

At the highest dose, participants lost nearly 19% of their body weight -- comparable to tirzepatide (Mounjaro) and significantly more than semaglutide alone. For a person weighing 110 kg, that is roughly 20.5 kg gone in under a year.

Clinical Trial Results: Fatty Liver Disease (MASH)

This is where survodutide truly stands apart. In a separate Phase 2 trial for MASH (Sanyal AJ et al., New England Journal of Medicine, 2024), the liver-specific results were striking:

Survodutide vs Ozempic vs Mounjaro vs Retatrutide

How does survodutide stack up against the other weight loss injections South Africans are talking about?

The standout difference: survodutide's liver data is in a league of its own. If you are someone dealing with both weight problems and fatty liver, this could become the drug of choice once it reaches the market.

Why Fatty Liver Disease Matters in South Africa

Fatty liver disease does not get the attention it deserves in South Africa. Here is why you should care:

• It is extremely common. Up to 30% of South African adults may have some degree of NAFLD/MASH. Rates are higher in people with obesity, type 2 diabetes, or metabolic syndrome.
• It is silent. Most people have no symptoms until the disease is advanced. By the time you feel something, you could already have significant liver fibrosis.
• It can progress to cirrhosis and liver cancer. MASH is now the fastest-growing cause of liver transplant referrals globally.
• It is linked to heart disease. People with MASH have a significantly higher risk of cardiovascular events -- the leading cause of death in SA.
• Current treatment is limited. Until recently, the only treatment was "lose weight and exercise." Now resmetirom (Rezdiffra) is approved in the US for MASH, but it is not available in South Africa and has modest efficacy.

If you have been diagnosed with fatty liver, or if you are overweight and have not had your liver checked, ask your GP for a liver function test and possibly a FibroScan. Early detection makes a massive difference.

Side Effects of Survodutide

Like all GLP-1 class drugs, survodutide comes with gastrointestinal side effects. In the Phase 2 obesity trial:

• Nausea: Reported in up to 41% of participants at higher doses (this typically decreases after the first few weeks)
• Diarrhoea: Up to 21%
• Vomiting: Up to 18%
• Constipation: Up to 11%
• Decreased appetite: This is technically the desired effect, but some patients found it too pronounced initially

The side effect profile is broadly similar to other GLP-1 drugs. Slow dose escalation (starting low and gradually increasing) helps manage these symptoms. Serious adverse events were rare in both Phase 2 trials.

When Will Survodutide Be Available in South Africa?

Here is the realistic timeline:

1. Phase 3 trials (ongoing, 2025-2027): Boehringer Ingelheim is running Phase 3 trials for both obesity (ACHIEVO programme) and MASH. Full results expected 2027.
2. US/EU regulatory submission (est. 2027-2028): If Phase 3 results are positive, Boehringer Ingelheim will submit for FDA and EMA approval first.
3. SAHPRA submission (est. 2028-2029): South African regulatory submission typically follows major markets by 6-12 months. SAHPRA approval can take an additional 12-24 months.
4. Pharmacy availability (est. 2029-2030): Once approved, distribution through Dis-Chem, Clicks, and private pharmacies. Medical aid scheme decisions will determine out-of-pocket cost.

The MASH indication could actually speed things up. With limited treatment options for fatty liver disease globally, regulators may prioritise review of survodutide -- similar to how Wegovy received expedited review for obesity in some markets.

Estimated Cost in South Africa

No official pricing exists yet, but we can estimate based on similar drugs:

• Ozempic (semaglutide 1mg): Currently around R3,000-R4,500/month in SA
• Wegovy (semaglutide 2.4mg): R4,000-R5,500/month where available
• Mounjaro (tirzepatide): Expected R3,500-R6,000/month
• Survodutide (estimated): R3,000-R6,000/month

The dual indication (obesity + MASH) could work in patients' favour for medical aid coverage. Schemes like Discovery Health, Bonitas, and Momentum may be more willing to fund a drug prescribed for liver disease than one prescribed purely for weight loss. This is a strategy worth discussing with your doctor and medical aid scheme once survodutide becomes available.

What You Can Do Now While Waiting for Survodutide

Survodutide is still years away from South African pharmacies. In the meantime, here are evidence-based steps you can take:

• Get your liver checked. Ask your GP for ALT/AST liver function tests. If results are abnormal, a FibroScan or ultrasound can assess liver fat and fibrosis.
• Consider available GLP-1 options. Ozempic is available now in SA and provides meaningful weight loss that also benefits liver health.
• Reduce refined carbs and sugar. Liver fat responds dramatically to dietary changes. A low-carb or Mediterranean-style diet can reduce liver fat by 30-50% even without weight loss drugs.
• Exercise regularly. Both aerobic exercise and resistance training reduce liver fat independently of weight loss. Aim for 150 minutes per week.
• Limit alcohol. Even moderate drinking combined with metabolic risk factors accelerates liver damage.
• Try intermittent fasting. Time-restricted eating has shown benefits for both weight management and liver enzyme levels in South African-relevant studies.
• Focus on protein intake. Adequate protein (biltong, eggs, chicken, legumes) supports muscle preservation during weight loss -- important because muscle loss is a concern with GLP-1 drugs.

The Bottom Line

Survodutide represents a genuine step forward in the obesity drug landscape -- not just because of its strong weight loss numbers, but because it directly addresses fatty liver disease, a condition that affects millions of South Africans silently.

For the roughly 30% of SA adults with some degree of fatty liver, and for anyone who is overweight and worried about long-term liver health, survodutide is a drug worth watching closely. It is not available yet, but the clinical data is compelling, and the dual obesity + MASH indication could make it easier to access through medical aid schemes once it arrives.

In the meantime, do not wait. The lifestyle interventions above -- diet, exercise, and available medications like Ozempic -- can make a real difference right now. And if you have not had your liver checked, make that appointment.

Last updated: June 2026. Sources: Blueher M et al., NEJM 2024 (Phase 2 obesity trial); Sanyal AJ et al., NEJM 2024 (Phase 2 MASH trial); Boehringer Ingelheim pipeline disclosures. This article will be updated as new data and SA-specific developments emerge.